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Chronic myelogenous leukemia (CML) accounts for 15-20% of all leukemia cases across the globe, with an
incidence of 1-2 people in every 100,000. Doxorubicin (DOX) is a popular anti-cancer chemotherapy drug
used to treat CML and has an IC50 of 0.412µM in the immortal K-562 cell line. Although DOX is effective in
destroying cancer cells, DOX affects other tissues as well. Unfortunately, DOX is often associated with
adverse physiological and psychological side effects, leading to decreased quality of life and survival.
Cannabidiol (CBD), a compound found in Cannabis Sativa, is a non-toxic exogenous agent with the potential
to reduce chemotherapy side effects including anxiety, inflammatory conditions, nausea, and inhibits human
breast cancer cell proliferation and tissue invasion. Given this therapeutic potential, the purpose of the present
investigation was to explore whether CBD would alter the ability of DOX to induce cell death in K-562 cells.
Briefly, 3 groups of 7.5x105K-562 cells were plated, cultured and incubated for 24h and 48h and treated with
both CBD and DOX in the following concentrations (CBD 1 and 5uM; DOX 1 and 5uM; CBD 1µM: DOX
5µM; CBD 5µM: DOX 1µM; CBD 1µM: DOX 1µM). Flow-cytometry was used following the 24h and 48h
incubation to determine cell viability using Calcenin-AM cell viability dye. Preliminary results revealed that
median fluorescence intensity of Calcenin-AM was lower than control at 24h (47710 MFI) in CBD
1µM:46909 and DOX 5µM:39740 MFI; all other groups MFI increased above control at 24h. Following 48h
only DOX 5uM MFI decreased below control. Both concentrations of DOX in combination with CBD resulted
in higher MFI than control and DOX 5uM. This suggests that higher concentrations of CBD alone and CBD in
combination with DOX, may increase K562 cancer cell proliferation in addition to interfere with K562 cancer
cell death upon DOX treatment. Although these results are preliminary; they are novel. This study provides a






Preliminary results revealed that the median fluorescence intensity of calcenin
AM was lower than control at 24h (47710 MFI) in CBD 1µM and DOX 5µM.
However, CBD 5µM and DOX 1µM had a higher MFI following 24h
incubation (Figure 1. and Table 1). Following 48h incubation only DOX 5μM
MFI decreased below control values, while CBD 5μM increased above control
values. All concentrations of DOX in combination with CBD resulted in higher
MFI than control (Figure 2). Cannabidiol at lower concentrations had no effect
on cancer cell viability; however, CBD at higher doses after 2 days of exposure,
increased cancer cell viability. A representative figure of the data obtained with
the flow cytometer is presented in Figure 3.Chronic myelogenous leukemia (CML) accounts for 15-20% of all leukemia cases across
the globe, with an incidence of 1-2 people in every 100,000. One of the more common anti-
cancer chemotherapy drugs used to treat CML is doxorubicin (DOX). Despite the ability of
DOX to effectively kill leukemia cells, DOX also damages non cancer cells leading to
adverse, potentially life threatening side effects. Cannabidiol (CBD) is a compound found in
cannabis and is most well-known for its potential to reduce the negative side effects of
chemotherapy. Although CBD inhibits human breast cancer cell proliferation and tissue
invasion, relatively little is known about how CBD may change the action of DOX on
leukemia cells.
The purpose of this novel investigation was to explore whether CBD would alter the 
ability of DOX to induce cell death in leukemia (K-562) cells. We hypothesized that the 
co-administration of CBD and DOX would increase the ability of DOX to induce cell death 
in K562 cells.
Briefly, K562 cells (ATCC, Manassas, VA) were seeded in a 6-well plate at a
density of 7.5x105 and treated with either DOX and/or CBD (1μM CBD; 5μM
CBD; 1μM DOX; 5μM DOX;1µM CBD+5µM DOX; 5µM CBD+1µM
DOX;1µM CBD+1µM DOX). Cultures were then incubated for 24 or 48h in the
atmosphere stated above. Calcein AM was thawed and resuspended in Dimethyl
sulfoxide and was incubated with cultures in the dark on ice for 20 minutes.
Then, cells were washed and resuspended in Dulbecco's phosphate buffered
saline. Cell cultures were then incubated with CD-71 on ice in the dark for 20
minutes, washed, resuspended, and read on the Attune™ NxT Flow Cytometer
(Thermo Fisher Scientific).
When cancer cells are treated with CBD alone or combination with DOX, cancer
cell viability increased. Therefore, we conclude that CBD, at 5μM concentration for
2 days, may interfere with DOX-induced cancer cell death. Given that some cancer
survivors use CBD to help with their pain, inflammation and anxiety management,
these individuals deserve to know whether CBD has the potential to interfere with
their chemotherapy. Although these results are preliminary in nature, they are
striking and suggest that future efforts should focus on whether CBD may
actually hinder that actions of DOX on cancer cells.
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(MFI) 47710 46909 51398 52808 39740 51051 63613 48185
48HR 
(MFI) 45656 46751 52987 46909 36764
Cell Culture: K562 cells were cultured in RPMI-1640 medium supplemented with 10%
Fetal Bovine Serum and 1% Penicillin Streptomycin at 37°C in a humidified atmosphere
of 5% CO2.
Cell Viability Assay: Cell viability was determined using calcein AM, which is a a cell-
permeant dye used to determine cell viability. When cells are alive, the nonfluorescent
calcein AM is converted to a green fluorescent calcein through cleavage of the
acetoxymethyl portion by cellular esterase. This fluorescence can be read on a flow
cytometer.
Table 1. Mean Fluorescence Intensity 
48h
24h
Figure 3. Flow Cytometry Cell Viability
K562 CBD 5µM DOX 5µM 
Figure 1. K562 Cell Viability
Figure 2. CBD+DOX
